Freezing the graft is not necessary for autotransplants for plasma cell myeloma and lymphomas.

Abstract:

:We studied rates of granulocyte and platelets recovery in 359 consecutive subjects receiving blood cell infusions in the context of autotransplants for plasma cell myeloma (N = 216) and lymphomas (N = 143). Blood cells were mobilised with filgrastim given for 4-5 days and collected after a median of 2 (range, 1-2) apheresis. Apheresis products were stored at 4° C for a median of 3 days (range, 2-6 days). Most subjects received carmustine, etoposide, cytarabine and melphalan (BEAM), cyclophosphamide, carmustine and etoposide (CBV) or high-dose melphalan. Filgrastim was given post transplant to 319 subjects. Median numbers of mononuclear cells collected was 31 × 10E + 6/kg (interquartile range (IQR) 37 × 10E + 6 cells/kg). Median numbers of CD34-positive cells collected was 3.6 × 10E + 6/kg (IQR 3.8 × 10E + 6/Kg). Median viability after collection was 90% (IQR 7%) after storage, 88% (IQR 12%). A total of 255 of 256 evaluable subjects recovered bone marrow function and there was no late bone marrow failure. Median interval to neutrophils >0.5 × E + 9/L was 13 days (range, 9-39 days) and to platelets >20 × 10E + 9/L, 16 days (range, 7-83 days). These rates and ranges seem comparable to those reported after autotransplants of frozen blood cells. There was no correlation between numbers of storage days at 4 °C and viability afte storage (r = -0.018, p = 0.14)) nor rates of recovery of neutrophils (r = -0.054, p = 0.52) or platelets (r = 0.116, p = 0.14). Blood cells collected for autotransplant can be stored at 4 °C for 6 d. This method is simple, inexpensive and widely applicable.

journal_name

Bone Marrow Transplant

authors

Kardduss-Urueta A,Gale RP,Gutierrez-Aguirre CH,Herrera-Rojas MA,Murrieta-Álvarez I,Perez-Fontalvo R,Ruiz-Delgado GJ,Ruiz-Rojas G,Jaimovich G,Feldman L,Labastida-Mercado N,Endara A,Castro M,Galindo-Becerra S,Cardona-Molina MA

doi

10.1038/s41409-017-0047-7

subject

Has Abstract

pub_date

2018-04-01 00:00:00

pages

457-460

issue

4

eissn

0268-3369

issn

1476-5365

pii

10.1038/s41409-017-0047-7

journal_volume

53

pub_type

杂志文章
  • Cryotherapy in the prevention of oral mucositis in patients receiving low-dose methotrexate following myeloablative allogeneic stem cell transplantation: a prospective randomized study of the Gruppo Italiano Trapianto di Midollo Osseo nurses group.

    abstract::Severe oral mucositis is a major cause of morbidity following allogeneic hematopoietic stem cell transplantation (AHSCT). Cryotherapy, that is, the application of ice chips on the mucosa of the oral cavity during the administration of antineoplastic agents, may reduce the incidence and severity of chemotherapy-related...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1038/sj.bmt.1705590

    authors: Gori E,Arpinati M,Bonifazi F,Errico A,Mega A,Alberani F,Sabbi V,Costazza G,Leanza S,Borrelli C,Berni M,Feraut C,Polato E,Altieri MC,Pirola E,Loddo MC,Banfi M,Barzetti L,Calza S,Brignoli C,Bandini G,De Vivo A,B

    更新日期:2007-03-01 00:00:00

  • Parenteral nutrition following intensive cytotoxic therapy: an exploratory study on the need for parenteral nutrition after various treatment approaches for haematological malignancies.

    abstract::Patients receiving intensive cytotoxic therapy are traditionally supported with parenteral nutrition (PN), although it is unclear whether all patients benefit from PN. This study aimed to identify regimen-associated differences in PN requirements, to reveal discrepancies between the number of PN indications and the fr...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701747

    authors: Iestra JA,Fibbe WE,Zwinderman AH,Romijn JA,Kromhout D

    更新日期:1999-05-01 00:00:00

  • Addition of low-dose busulfan to cyclophosphamide in aplastic anemia patients prior to allogeneic bone marrow transplantation to reduce rejection.

    abstract::Busulfan was added at the dose of 4 mg/kg to 200 mg/kg cyclophosphamide in 81 patients (3-53 years, median 24) with aplastic anemia to reduce graft rejection. Graft-versus-host disease (GVHD) prophylaxis comprised cyclosporine-methotrexate. The number of prior transfusions was 0-276 (median 26), and 48% had received p...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1038/sj.bmt.1704325

    authors: Dulley FL,Vigorito AC,Aranha FJ,Sturaro D,Ruiz MA,Saboya R,Macedo MC,Da Silva RL,Chamone DA,Mehta J,Bacigalupo A,De Souza CA

    更新日期:2004-01-01 00:00:00

  • Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma.

    abstract::High-dose melphalan (HDM) has been adopted as standard therapy in the treatment of multiple myeloma. This treatment is associated with non-selective cytotoxicity, causing oral mucositis as the major non-hematological side-effect. Amifostine is a cytoprotector which prevents toxicity induced by anticancer therapy. We p...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1703757

    authors: Thieblemont C,Dumontet C,Saad H,Roch N,Bouafia F,Arnaud P,Hequet O,Espinouse D,Salles G,Roy P,Eljaafari-Corbin A,Du Manoir-Baumgarten C,Coiffier B

    更新日期:2002-12-01 00:00:00

  • Minimal residual disease testing after stem cell transplantation for multiple myeloma.

    abstract::Increased use of novel agents and autologous stem cell transplantation has led to a significant improvement in PFS and overall survival in patients with multiple myeloma. Despite improved treatment strategies, most patients eventually relapse due to persistent low levels of disease in the bone marrow. Increasingly sen...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/bmt.2015.164

    authors: Sherrod AM,Hari P,Mosse CA,Walker RC,Cornell RF

    更新日期:2016-01-01 00:00:00

  • Human herpesvirus 6 is an important pathogen in infectious lung disease after allogeneic bone marrow transplantation.

    abstract::Two hundred and ten bronchoalveolar lavage (BAL) samples were obtained from 50 patients 10 days before and on defined days after allogeneic bone marrow transplantation (BMT). The samples were examined for human cytomegalovirus (HCMV) and human herpesvirus-6 (HHV-6) by polymerase chain reaction (PCR). Fifteen patients ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702569

    authors: Buchbinder S,Elmaagacli AH,Schaefer UW,Roggendorf M

    更新日期:2000-09-01 00:00:00

  • Curative treatment of autosomal-recessive hyper-IgE syndrome by hematopoietic cell transplantation.

    abstract::Autosomal-recessive hyper-IgE syndrome (AR-HIES) is a combined immunodeficiency recently found to be associated with mutations of DOCK8. Clinically, this disorder is characterized beside recurrent bacterial complications, in particular by an unusual susceptibility to extensive cutaneous viral complications and by a hi...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2010.169

    authors: Gatz SA,Benninghoff U,Schütz C,Schulz A,Hönig M,Pannicke U,Holzmann KH,Schwarz K,Friedrich W

    更新日期:2011-04-01 00:00:00

  • Hemopoietic stem cell processing: comparison of progenitor cell recovery using the Cobe 2991 cell washer and the Haemonetics V50 apheresis system.

    abstract::Using 24 bone marrow (BM) harvests intended for cryopreservation and transplantation, we compared the use of the Cobe 2991 cell washer (2991) and the Haemonetics V50 apheresis system (HV50) for automated BM processing. Our in vitro data indicate that while the mononuclear cell (MNC) concentration of the HV50 product w...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Preti RA,Ahmed T,Ayello J,Helson L,Argani I,Wuest D,Ciavarella D

    更新日期:1992-05-01 00:00:00

  • Fixed-dose single administration of Pegfilgrastim vs daily Filgrastim in patients with haematological malignancies undergoing autologous peripheral blood stem cell transplantation.

    abstract::Infectious complications are frequent events in patients undergoing high-dose cytotoxic chemotherapy with subsequent autologous peripheral blood stem cell transplantation (PBSCT). To evaluate whether a single subcutaneous injection of pegfilgrastim (6 mg) is as safe and effective as daily filgrastim (5 mug/kg/day), 60...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704927

    authors: Staber PB,Holub R,Linkesch W,Schmidt H,Neumeister P

    更新日期:2005-05-01 00:00:00

  • High interleukin-10 serum levels are associated with fatal outcome in patients after bone marrow transplantation.

    abstract::IL-10 plays an important role in the control of immune reactions during systemic infection. Here, IL-10 serum levels were investigated in patients after BMT. The IL-10 levels correlated with the clinical course of the patients and with serum levels of C-reactive protein (CRP) and neopterin (NP). A total of 26 patients...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1700902

    authors: Hempel L,Körholz D,Nussbaum P,Bönig H,Burdach S,Zintl F

    更新日期:1997-09-01 00:00:00

  • Mobilization of PBSCs with chemotherapy and recombinant human G-CSF: a randomized evaluation of early vs late administration of recombinant human G-CSF.

    abstract::The optimal timing for recombinant human (rh)G-CSF administration after chemotherapy for PBSC mobilization has not yet been determined. In this study, we compared two different time schedules of rhG-CSF; 4th (early) vs 7th day (late), in 48 consecutive patients with multiple myeloma and lymphoma undergoing PBSC mobili...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1038/bmt.2009.161

    authors: Ozcelik T,Topcuoglu P,Beksac M,Ozcan M,Arat M,Biyikli Z,Bakanay SM,Ilhan O,Gurman G,Arslan O,Demirer T

    更新日期:2009-12-01 00:00:00

  • Clonality studies in patients undergoing allogeneic and autologous bone marrow transplantation for haematological malignancies.

    abstract::Twenty three allogeneic bone marrow transplant (BMT) patients with female donors and 23 female autologous transplant patients were assessed for clonality status after transplant to determine the nature of haemopoietic reconstitution. The X chromosome probes PGK, HPRT and M27 beta were used to assess clonality by analy...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Saunders MJ,Jowitt SN,Yin JA

    更新日期:1995-01-01 00:00:00

  • Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing.

    abstract::In patients with acute myeloid leukemia (AML) consolidation treatment options are between allogeneic hematopoietic stem cell transplantation (HCT) and chemotherapy, based on disease risk at the time of initial presentation and age. Measurable residual disease (MRD) following induction chemotherapy could be incorporate...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-01165-x

    authors: Ahn JS,Kim T,Jung SH,Ahn SY,Jung SY,Song GY,Kim M,Yang DH,Lee JJ,Choi S,Lee JY,Park SK,Moon JH,Lee HY,Kim KH,Cai Y,Yi SY,Novitzky-Basso I,Zhang Z,Kim HJ,Kim DDH

    更新日期:2020-12-05 00:00:00

  • The recovery of resistance to alloengraftment following lethal irradiation and administration of T cell-depleted syngeneic bone marrow.

    abstract::Recent studies from this laboratory have shown that unmanipulated, MHC-mismatched allogeneic bone marrow (BM) engrafts and produces complete allogeneic chimerism when administered to recipient mice 8 days following lethal irradiation and reconstitution with T cell-depleted (TCD) syngeneic bone marrow. Host lymphopoiet...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Chester CH,Sykes M,Sachs DH

    更新日期:1989-03-01 00:00:00

  • Salivary immunoglobulins in recipients of bone marrow grafts. II. Transient secretion of donor-derived salivary IgA following transplantation of T cell-depleted bone marrow.

    abstract::Patients undergoing bone marrow transplantation (BMT) have decreased levels of salivary Ig over long periods of time. However, shortly after transplantation, a transient rise of Ig concentration in their saliva gland is detected. In order to trace the origin of this Ig, seven BM donors were immunized with tetanus toxo...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Chaushu S,Chaushu G,Garfunkel A,Slavin S,Or R,Yefenof E

    更新日期:1994-12-01 00:00:00

  • Mucosal melanoma following autologous stem cell transplantation for non-Hodgkin's lymphoma (NHL).

    abstract::The incidence of secondary malignancy following autologous stem cell transplantation (ASCT) is increasing. We describe a patient with stage IVB Hodgkin's disease who developed primary amelanotic malignant melanoma of the tongue 18 months following autologous stem cell transplantation. She was treated by partial glosse...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Ben-Yosef R,Braverman I,Saah D,Nagler R,Shohat S,Or R,Nagler A

    更新日期:1996-11-01 00:00:00

  • Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation.

    abstract::Human cytomegalovirus (CMV) is a major cause of death after transplantation. The frequency of pp65-specific T cells was examined in 38 HLA-A2+ stem cell recipients during the first year after transplantation. Patients were divided into four groups based on donor/recipient serostatus: d+/r+ (n=17), d+/r- (n=7), d-/r+ (...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究

    doi:10.1038/sj.bmt.1705585

    authors: Ganepola S,Gentilini C,Hilbers U,Lange T,Rieger K,Hofmann J,Maier M,Liebert UG,Niederwieser D,Engelmann E,Heilbronn R,Thiel E,Uharek L

    更新日期:2007-03-01 00:00:00

  • Social outcome in children treated by haematopoietic cell transplant for congenital immunodeficiency.

    abstract::Previous studies have reported increased rates of social difficulties in children treated by haematopoietic cell transplant (HCT). This study assessed social functioning in children with congenital immunodeficiency treated by HCT and investigated two potential underlying mechanisms that may explain social difficulties...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2010.318

    authors: Skucek E,Butler S,Gaspar HB,Titman P

    更新日期:2011-10-01 00:00:00

  • Effect of autologous hematopoietic stem cell transplantation on multiple sclerosis and neuromyelitis optica spectrum disorder: a PRISMA-compliant meta-analysis.

    abstract::We should consider both the treatment effects and adverse effects of autologous hematopoietic stem cell transplantation (AHSCT) on multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD). Articles exploring the effect and safety of AHSCT in the treatment of MS and NMOSD and published before Decembe...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-0810-z

    authors: Zhang P,Liu B

    更新日期:2020-10-01 00:00:00

  • Elevated lactate dehydrogenase is an adverse predictor of outcome in HLA-matched sibling bone marrow transplant for acute myelogenous leukemia.

    abstract::Prognostic factors for survival following allogeneic BMT for AML include age, disease status and cytogenetic risk classification. Lactate dehydrogenase (LDH) levels have not been studied as a potential risk factor. We reviewed our experience with BMT for AML and included LDH at the time of admission in an analysis of ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1705811

    authors: Kalaycio M,Rybicki L,Pohlman B,Dean R,Sweetenham J,Andresen S,Sobecks R,Sekeres MA,Advani A,Brown S,Bolwell B

    更新日期:2007-10-01 00:00:00

  • GM-CSF-mobilized peripheral blood CD34+ cells differ from steady-state bone marrow CD34+ cells in adhesion molecule expression.

    abstract::To determine the effect of growth factor mobilization on the expression of adhesion molecules, we compared CD34+ progenitor cell (PC) populations from steady-state bone marrow (BM) with granulocyte-macrophage colony-stimulating factor (GM-CSF)-mobilized apheresis products (peripheral blood stem cell (PSC)) using flow ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1700814

    authors: Watanabe T,Dave B,Heimann DG,Lethaby E,Kessinger A,Talmadge JE

    更新日期:1997-06-01 00:00:00

  • Risk of relapse in patients receiving azithromycin after allogeneic HSCT.

    abstract::Following publication of the ALLOZITHRO trial, the FDA released a safety announcement warning that azithromycin should not be given long-term to prevent BOS in patients with a blood or lymph cancer who have undergone allogeneic HSCT. Our site typically initiated azithromycin when patients were diagnosed with BOS post-...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-01095-8

    authors: Kutzke JL,Merten JA,Taraba JL,Mara KC,Shah MV,Hashmi SK,Patnaik MM,Litzow MR,Hogan WJ,Alkhateeb HB

    更新日期:2020-10-31 00:00:00

  • Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization.

    abstract::Plerixafor is an inhibitor of CXCR-4 (CXC chemokine receptor-4)/SDF (stromal cell-derived factor)-1 binding used in combination with granulocyte colony-stimulating factor (G-CSF) for mobilization of autologous peripheral blood hematopoietic stem cells (HSCs). We developed a data-generated, cost-saving decision-making ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2010.78

    authors: Costa LJ,Alexander ET,Hogan KR,Schaub C,Fouts TV,Stuart RK

    更新日期:2011-01-01 00:00:00

  • Therapeutic effect of umbilical cord serum eyedrops for the treatment of dry eye associated with graft-versus-host disease.

    abstract::This study was performed to investigate the therapeutic effect of umbilical cord serum eyedrops on dry eye associated with graft-versus-host disease (GVHD). Twenty-four eyes of 12 patients with severe dry eye syndrome associated with GVHD were treated with 20% umbilical cord serum eyedrops. Symptom scoring, corneal se...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1705566

    authors: Yoon KC,Jeong IY,Im SK,Park YG,Kim HJ,Choi J

    更新日期:2007-02-01 00:00:00

  • Impact of high-dose chemotherapy on antigen-specific T cell immunity in breast cancer patients. Application of new flow cytometric method.

    abstract::The present study analyses the influence of high-dose chemotherapy (HD) and autologous stem cell transplantation on natural and vaccine-induced specific immunity in breast cancer patients. Peripheral blood was collected from five breast cancer patients at serial time points in connection with treatment and in a follow...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703521

    authors: Svane IM,Nikolajsen K,Hansen SW,Kamby C,Nielsen DL,Johnsen HE

    更新日期:2002-04-01 00:00:00

  • Bone marrow graft as a source of allogeneic hematopoietic stem cells in patients undergoing a reduced intensity conditioning regimen.

    abstract::In an attempt to reduce the incidence of chronic GVHD (cGVHD) after reduced-intensity conditioning (RIC), we used BM instead of PBSC and added melphalan 100 mg/m(2) to the classical association of fludarabine, 30 mg/m(2)/day for 3 days and TBI, 200 cGy (FLUIM regimen). Between 2000 and 2012, 51 patients received BM wi...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2014.193

    authors: Gomez E,Duléry R,Langlois C,Coiteux V,Terriou L,Magro L,Gauthier J,de Berranger E,Duhamel A,Yakoub-Agha I

    更新日期:2014-12-01 00:00:00

  • Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT.

    abstract::This retrospective analysis compared two regimens of fludarabine combined with i.v. BU 6.4 mg/kg (FB2) or BU 12.8 mg/kg (FB4) for allografting of AML in first CR. A total of 437 patients (median age: 50 years) were administered FB2 (n = 225, 51%) or FB4 (n = 212, 49%). Median follow-up time was 28 months. Use of FB2 r...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究

    doi:10.1038/bmt.2014.133

    authors: Kharfan-Dabaja MA,Labopin M,Bazarbachi A,Hamladji RM,Blaise D,Socié G,Lioure B,Bermudez A,Lopez-Corral L,Or R,Arcese W,Fegueux N,Nagler A,Mohty M

    更新日期:2014-09-01 00:00:00

  • Towards a global system of vigilance and surveillance in unrelated donors of haematopoietic progenitor cells for transplantation.

    abstract::Safety of living donors is critical to the success of blood, tissue and organ transplantation. Structured and robust vigilance and surveillance systems exist as part of some national entities, but historically no global systems are in place to ensure conformity, harmonisation and the recognition of rare adverse events...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2013.104

    authors: Shaw BE,Chapman J,Fechter M,Foeken L,Greinix H,Hwang W,Phillips-Johnson L,Korhonen M,Lindberg B,Navarro WH,Szer J

    更新日期:2013-11-01 00:00:00

  • Extent of variability inherent in measurements of CD34-positive cells in different human haemopoietic tissues.

    abstract::Estimation of CD34 expression is widely used to detect and quantify progenitor cells in haemopoietic tissues used as stem cell sources for transplantation. Mouse monoclonal antibodies to CD34 recognise different epitopes of the mucin-like sialoglycoprotein. These epitopes can be grouped into three classes by their dif...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Titley I,Healy LE,Scott M,Amos TA,Gordon MY

    更新日期:1995-10-01 00:00:00

  • Economic evaluation of posaconazole vs fluconazole in the prevention of invasive fungal infections in patients with GVHD following haematopoietic SCT.

    abstract::Posaconazole has been proven to be as effective as fluconazole in the prevention of invasive fungal infections (IFI) in allogeneic haematopoietic SCT patients with GVHD. We assessed, from the perspective of the Spanish National Health Service, the cost-effectiveness of posaconazole vs fluconazole in preventing IFI. A ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2009.272

    authors: de la Cámara R,Jarque I,Sanz MA,Grau S,Casado MA,Sabater FJ,Carreras E

    更新日期:2010-05-01 00:00:00